These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36838749)

  • 41. Cannabinoid CB
    Olianas MC; Dedoni S; Onali P
    Life Sci; 2021 Jul; 276():119407. PubMed ID: 33794254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cryo-EM Structure of the Human Cannabinoid Receptor CB2-G
    Xing C; Zhuang Y; Xu TH; Feng Z; Zhou XE; Chen M; Wang L; Meng X; Xue Y; Wang J; Liu H; McGuire TF; Zhao G; Melcher K; Zhang C; Xu HE; Xie XQ
    Cell; 2020 Feb; 180(4):645-654.e13. PubMed ID: 32004460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
    Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
    Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
    Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cannabinoid CB
    Li AL; Carey LM; Mackie K; Hohmann AG
    J Pharmacol Exp Ther; 2017 Aug; 362(2):296-305. PubMed ID: 28592614
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In Vitro and In Silico Studies of Neolignans from
    Pandey P; Kumarihamy M; Chaturvedi K; Ibrahim MAM; Lambert JA; Godfrey M; Doerksen RJ; Muhammad I
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770918
    [No Abstract]   [Full Text] [Related]  

  • 47. A pharmacoinformatic approach on Cannabinoid receptor 2 (CB2) and different small molecules: Homology modelling, molecular docking, MD simulations, drug designing and ADME analysis.
    Vijayakumar S; Manogar P; Prabhu S; Pugazhenthi M; Praseetha PK
    Comput Biol Chem; 2019 Feb; 78():95-107. PubMed ID: 30500557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.
    Alqarni M; Myint KZ; Tong Q; Yang P; Bartlow P; Wang L; Feng R; Xie XQ
    Biochem Biophys Res Commun; 2014 Sep; 452(3):334-9. PubMed ID: 25148941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB
    Qian HY; Wang ZL; Chen LL; Pan YL; Xie XY; Xie X; Chen JZ
    ChemMedChem; 2018 Nov; 13(22):2455-2463. PubMed ID: 30246417
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
    Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
    Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Highly Selective, Amine-Derived Cannabinoid Receptor 2 Probes.
    Westphal MV; Sarott RC; Zirwes EA; Osterwald A; Guba W; Ullmer C; Grether U; Carreira EM
    Chemistry; 2020 Jan; 26(6):1380-1387. PubMed ID: 31961047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
    Han S; Zhang FF; Qian HY; Chen LL; Pu JB; Xie X; Chen JZ
    Eur J Med Chem; 2015 Mar; 93():16-32. PubMed ID: 25644673
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Latest advances in cannabinoid receptor agonists.
    Thakur GA; Tichkule R; Bajaj S; Makriyannis A
    Expert Opin Ther Pat; 2009 Dec; 19(12):1647-73. PubMed ID: 19939187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
    González-Naranjo P; Pérez-Macias N; Campillo NE; Pérez C; Arán VJ; Girón R; Sánchez-Robles E; Martín MI; Gómez-Cañas M; García-Arencibia M; Fernández-Ruiz J; Páez JA
    Eur J Med Chem; 2014 Feb; 73():56-72. PubMed ID: 24378710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
    Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
    Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of cannabinoid 1 and, 2 receptors and the effects of cannabinoid 1 and, 2 receptor agonists on detrusor overactivity associated with bladder outlet obstruction in rats.
    Kim SD; Cho KJ; Kim JC
    BMC Urol; 2017 Dec; 17(1):121. PubMed ID: 29284441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Opposing roles of CB
    Gobira PH; Oliveira AC; Gomes JS; da Silveira VT; Asth L; Bastos JR; Batista EM; Issy AC; Okine BN; de Oliveira AC; Ribeiro FM; Del Bel EA; Aguiar DC; Finn DP; Moreira FA
    Br J Pharmacol; 2019 May; 176(10):1541-1551. PubMed ID: 30101419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands.
    Ragusa G; Bencivenni S; Morales P; Callaway T; Hurst DP; Asproni B; Merighi S; Loriga G; Pinna GA; Reggio PH; Gessi S; Murineddu G
    ChemMedChem; 2018 Jun; 13(11):1102-1114. PubMed ID: 29575721
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological actions of cannabinoids.
    Pertwee RG
    Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
    [TBL] [